Survodutide Shows 16.6% Weight Loss in Phase 3 Trial, Could Rival Zepbound for Obesity and Liver Disease Treatment
Survodutide, a next-generation GLP-1 drug, achieved a 16.6% reduction in body weight in a Phase 3 trial, outperforming placebo by over 13%. The dual-a...